Post-effective amendment to a registration statement that is not immediately effective upon filing

Revenue - Additional Information (Detail)

v3.3.1.900
Revenue - Additional Information (Detail)
SFr in Millions
 1 Months Ended 12 Months Ended
Aug. 31, 2011
USD ($)
Tranches
Dec. 31, 2015
USD ($)
Dec. 31, 2015
CHF (SFr)
Dec. 31, 2014
USD ($)
Deferred Revenue Arrangement [Line Items]        
Revenues from product sales   $ 0    
Revenue   2,931,931   $ 5,365,054
Collaboration agreement, milestone payments   $ 2,538,698   3,184,988
Collaboration agreement, license upfront payment       473,039
BIO Cluster M4 [Member]        
Deferred Revenue Arrangement [Line Items]        
Funding rate   40.00% 40.00%  
Grant received   $ 8,654   100,000
BIO Cluster M4 [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   1,400,000    
European Union [Member] | Seventh Research Framework Program (FP7 Agreement) [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments $ 7,300,000      
Funding rate 64.00%      
Grant received   400,000   700,000
Tranches of payments | Tranches 3      
Amount payable to other members of the consortium   400,000   300,000
Collaborative Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments   0   0
Contractual agreement, potential payments   14,000,000    
Sanofi [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   50,400,000    
Sanofi [Member] | Maximum [Member] | Research Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   1,900,000    
Sanofi [Member] | Maximum [Member] | Development Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   28,900,000    
Sanofi [Member] | Maximum [Member] | Commercial Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   19,600,000    
Sanofi [Member] | Collaborative Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, revenue recognized   500,000   1,400,000
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments   2,000,000   3,000,000
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   89,100,000    
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   2,600,000    
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   36,500,000    
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   49,100,000    
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Contractual agreement, potential payments   900,000    
FHoffmann La Roche Ltd And Hoffmann La Roche Inc [Member] | Upfront Payment Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, license upfront payment   $ 6,500,000    
FHoffmann La Roche Ltd And Hoffmann La Roche Inc [Member] | Research Services [Member]        
Deferred Revenue Arrangement [Line Items]        
Research collaboration agreement, estimated period   20 months 20 months  
FHoffmann La Roche Ltd And Hoffmann La Roche Inc [Member] | Research Services [Member] | Extension Term [Member]        
Deferred Revenue Arrangement [Line Items]        
Research collaboration agreement, estimated period   5 years 5 years  
FHoffmann La Roche Ltd And Hoffmann La Roche Inc [Member] | Research Collaboration and License Agreement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments   $ 415,700,000 SFr 415.0  
Research collaboration agreement, Termination description   The agreement may be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is not dismissed or such breach is not cured within 90 days; or (ii) after 15 months from the effective date of the agreement, by Roche as a whole or on a product-by-product and/or country-by-country basis upon 90 days prior written notice before the first commercial sale of a product or upon 180 days prior written notice after the first commercial sale of a product. Roche may also, in its sole discretion, terminate the agreement upon a change of control of Pieris involving a company that develops or commercializes biopharmaceutical products. The agreement may be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is not dismissed or such breach is not cured within 90 days; or (ii) after 15 months from the effective date of the agreement, by Roche as a whole or on a product-by-product and/or country-by-country basis upon 90 days prior written notice before the first commercial sale of a product or upon 180 days prior written notice after the first commercial sale of a product. Roche may also, in its sole discretion, terminate the agreement upon a change of control of Pieris involving a company that develops or commercializes biopharmaceutical products.  
Collaboration Partner One [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]        
Deferred Revenue Arrangement [Line Items]        
Revenue   $ 2,000,000   3,000,000
Collaboration Partner Two [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]        
Deferred Revenue Arrangement [Line Items]        
Revenue   500,000   1,400,000
Government Grant [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]        
Deferred Revenue Arrangement [Line Items]        
Revenue   $ 400,000   $ 700,000